The Waiting Game Sends Geron Corporation Lower By Another 18% In October

Image source: Getty Images.Shares of Geron Corporation (NASDAQ: GERN), a clinical-stage small-cap biotech focused on the development of treatments for cancer, plunged 18% in October based on data from S&P Global Market Intelligence. The reason for the drop can likely be traced to the impatience of investors.In September, Geron and licensing partner Johnson & Johnson (NYSE: JNJ) (via its subsidiary Janssen Pharmaceuticals) provided updates on two critical studies involving Geron's lead drug, imetelstat.Continue reading

BING NEWS:
  • Titans Add Tackle Depth, Sign Geron Christian
    Read the recent NFL news and rumors for fantasy football. The Tennessee Titans signed offensive tackle Geron Christian on Wednesday, according ...
    06/12/2024 - 9:59 am | View Link
  • Geron: Innovative Rytelo Enters A Challenging MDS Market
    FDA approves Geron's Rytelo for low-risk MDS patients, but stiff competition and need for more capital suggest selling stock. See why GREN stock is sell rated.
    06/8/2024 - 1:00 am | View Link
  • Geron Corporation: FDA Approval Fuels Stock Price Surge
    The recent FDA approval of RYTELO™ (imetelstat) has propelled Geron Corporation (NASDAQ: GERN) into the spotlight, sparking a surge in Geron's stock price and attracting heightened attention from ...
    06/7/2024 - 5:56 am | View Link
  • More

 

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More Business News